NTLA

Equivalent-Aside-404

Thanks for the treatment cost numbers. 5 million per patient over 10 years for potentially 10K patients that are candidates for current available therapy is $50B. Makes even more sense to just hold NTLA long and add to my position and just ride the ups and downs.

ADD-DDS

I have an agentic debate for vibe investing: NTLA (Intellia): The Bull Case Has a Hole You Should Know About The Setup A bull thesis is circulating: Intellia crushed HAE Phase 3 data (87% attack reduction, super clean safety), stock got beat down on dilution, now shorts are trapped. Squeeze incoming. The thesis is partially real. The clinical data is solid. But it’s missing the single most important fact of the last 8 months, and that changes everything. What the Bull Case Got Right ✅ HAE data is genuinely good: 87% reduction in attack rate, 62% of patients attack-free for 6+ months, zero serious adverse events in this trial. ✅ Regulatory path is real: Rolling BLA submission underway, targeting H1 2027 launch. One-time IV infusion beats lifelong twice-weekly prophylaxis. Commercial moat exists. ✅ Balance sheet is fine: \~$670M cash (Q3’25) + $180M raise in May = runway into mid-2027, maybe later. No dilution death spiral coming. ✅ Shorts do exist: \~34% of float short. A pop could trigger covering. What the Bull Case Left Out 🚨 A patient died from liver toxicity on the same platform in October 2025. The facts: • nex-z (Intellia’s ATTR therapy, same LNP/Cas9 platform as HAE lonvo-z) dosed a patient Sept 30, 2025 • That patient developed Grade 4 liver transaminase elevations and bilirubin spike • Patient was hospitalized → FDA placed clinical holds on both MAGNITUDE trials (Oct 29) → patient died Nov 5 • Holds were lifted in Jan-Mar 2026 after the company promised enhanced liver monitoring This death sits on the exact same delivery platform that the bull thesis claims is “validated” by the HAE data. That’s the wrong read-across. The Real Situation HAE lonvo-z: De-risked. Clean data. Realistic 2027 launch. This is the actual asset. ATTR nex-z: Alive but wounded. Was supposed to be the platform’s exponential call option. Now it’s a “will the liver toxicity recur” binary. The holds being lifted doesn’t erase that you watched an 80-year-old die from liver injury on this exact mechanism. Squeeze narrative: Stale. The 87% number broke in May; June was just conference detail. Clinical catalysts for NTLA average a -0.44% move. Don’t expect shorts to panic into covering on old news. The Grid | |Bull |Bear | |-------------------|---------------|---------------------------------| |\*\*HAE data\*\* |✅ Real & good |✅ Agree | |\*\*Regulatory path\*\*|✅ Rolling BLA |⚠️ Binary on FDA response to nex-z| |\*\*Platform safety\*\*|❌ Ignores death|🔴 Death on same mechanism is huge| |\*\*Squeeze setup\*\* |Shorts exist |Old catalyst, poor base rates | |\*\*nex-z upside\*\* |Free call |Survivability question now | Bottom Line If you love the HAE asset: Fair entry argument exists. One-time therapy, orphan disease, runway secured. If you came for the squeeze: The catalyst is a month old, clinical newsflow for NTLA historically doesn’t move the stock, and shorts aren’t forced into anything yet. What’s actually priced in: A company with one solid near-term asset (HAE) and one scarred pipeline asset (nex-z) that needs to prove liver toxicity was patient-specific, not mechanism-linked. That’s not “de-risked platform validated.” That’s “one leg works, other leg is on crutches.” Trade accordingly. Don’t let a clean HAE readout blind you to the fact that this platform killed someone 7 months ago. TL;DR: HAE data is real. Regulatory path is real. But the bull thesis erased a treatment-related patient death on the same delivery platform, which is… not ideal. This is a one-asset story now, not a platform story.

Equivalent-Aside-404

NTLA doesn’t have the parameters of a short squeeze like LFVN but it will have some price momentum with the weekend news and newly published study in the NEJM. Maybe too late to get in, though. Thread on NTLA has started in this group. I am not shitting on LFVN. I love the parameters, but I don’t see or expect a catalyst. New CEO news and financial stability are baked in. I do see high CTB but I feel the I and the other retail investors are out of our league playing against the sophisticated hedgers handling the shorts. But what do I know. I want to see the LFVN group kill it with a squeeze so good luck all.

NiceGuy0606

Your observation about the June 4th price action is right. If new shorts piled in at the $14 level, a major gap-up on Monday is going to put them under immediate pressure, even if the overall squeeze parameters look calm on paper.The competition from existing mAbs and RNA therapies is real, and market penetration will be a steady climb. However, the cost economics are what most shorts completely miss. HAE is one of the most expensive chronic conditions in the world. takzyhro/ Orladeyo cost insurers roughly 500 k per Patient every year. Over 10 years, a single well-controlled patient costs health insurance $5M+. Intellia is likely to cost less than this. But the true macro comed from Platform validation. Proving that the in-vivo delivery mechanism is safe and durable in a Phase 3 trial completely changes the risk profile for NTLA's entire pipeline (like ATTR).

Equivalent-Aside-404

I’ve seen that NTLA has 2.7 million shares to borrow. The short interest was 34% last reporting(Schwab). There was a bump in price 6/4/26 to over 14. I suspect at that time there have been new shorts with the price rise, in addition I suspect some shorts were churned with the pressure of positive news on FDA clearance of one of NTLA’s other trials and institutional investing. How the shorts play this with the current news I do not have the sophisticated knowledge to even make a guess. There are two other companies to compete with one using monoclonal antibodies and is in stage three the other is an RNA-targeted prophylactic therapy that is already commercially available(Gemini AI). I don’t have any biotech or pharmaceutical experience to know how competitive this will be for NTLA. It does appear that this is an effective and safe treatment. The disease HEA itself can be life threatening. The prevalence in the US is estimated to be up to 10,000 people those many of those may be unreported. So there is not a huge market, but it is great news because it validates NTLA as a serious player in the genetic engineering biotech field. I believe this will squeeze due to price momentum from the news, not necessarily due to great squeeze parameters, and am hoping for it to rise to at least 15 and maybe even 18 based on previous charts. I have been increasing my shares, now 700, with some calls. I’ll probably dump some shares above 15 and see where it consolidates before getting in again, or maybe not, because the company is expecting approval this year for this drug and the FDA has cleared their other drug trial to resume.

Professional_Help_85

Biotech nerds, is the NTLA news actually bullish or should I expect to baghold even longer?

Equivalent-Aside-404

If you do take a look at NTLA let me know what you think. Give me your bearish thoughts at least.

Equivalent-Aside-404

I’m no fan of MLM anyway so no reason to hold LFVN any longer. I’m tied up this week but next week I’m going to be looking at PCT. Not a squeeze potential now, may be never but I like the business. Also, NTLA has high short interest and they are reporting at the EAACI scientific conference this weekend. I’m long but if there’s a good spike I am not married to it.

dvdmovie1

There have already been hyped up names around AI drug discovery like RXRX; a name that I said a while ago that I thought was a short and wish I would have. "$CRSP, $NTLA, and $BEAM" All Ark-y names that have generally not traded that well over the last 5 years or so. I like investing in biotech, but don't own any of these. " $ILMN is building the infrastructure behind the industry," I'd rather own TMO than ILMN but life science has continued to be awful post-covid given overcapacity and other issues. I think AI would be particularly useful in terms of things like medical imaging - not long those names but that hasn't worked out well yet either - GEHC and the rest of medtech have had a lousy year. I'd like healthcare to be a more meaningful beneficiary of AI but I have yet to see the kind of meaningful progress I'd like. Most of it has been hype with little to show for it (rxrx)

Equivalent-Aside-404

Gotcha. I’ve got other biotech and early stage pharmaceuticals. Totals are less than 5% of my portfolio. But NTLA is my favorite so far so I plan to push my investments on it a bit more. I’m holding long and also it’s kind of a side show for me so I can tolerate loss on it. Good luck to us!

Brainiacish

Don’t forget NTLA

No_Acanthaceae_2198

FJET when it's under $5, ONDS under $9.20, NTLA under $12 (really, under $13), OSG still due to gain another $2, RIVN under$14, FIG and CELH will climb at some point over the summer, INFQ always a buy now under $12. I know some aren't pennies.

RevolutionaryPhoto24

NTLA and GRRR have insane earnings and revenue growth. ZS, too. Looking to buy LEAPS on the last one (already hold them on the first two.)

Optimal_Reserve_9649

I follow her ark fund daily and also wonder why the purchases in NTLA and ACHR.

VictoriaAutNihil

I just sold some and some NVDA, MRVL. Bought 1000 shares of NTLA @ 13.53. I don't always follow Cathie Wood, but I believe she's on to something with Intellia Therapeutics. They use CRSPR technology. I recently bought CRSP 500 shares @ 55.08, of which Wood has been buying that as well. She also recently unloaded some of her AMD position.

yellowfromtheegg69

NTLA Guys!!!

nemodigital

Yeah NTLA had a nice pop today even after the share dilution. I really think biotech is going to do magnificently well esp combined with AI. I've grabbed a few of her other picks from ARKG that I like including PACB

Snoo23417

Hope she's right about NTLA too. Got a bunch of eggs in that basket.

Stunning-Narwhal1884

the short interest on NTLA and watching it each day die is criminal

No_Acanthaceae_2198

Adding a comment to keep the sub alive! Jumped in the dip of NTLA last night (not a penny), trading on SAFX today, watching ATER.

Venice_LA

bio tech always a dumb choice, signed guy who lost 150k in NTLA alone a few years ago

BlakeTheDog

NTLA is such a tease, up 30% premarket just to close at -6% for the day.

Snoo23417

NTLA suffering from the Cathy Wood curse. From up 25% premarket to down 8% now.

Snoo23417

NTLA was up 25% premarket, then it opened 2% up. Sometimes you are just not meant to win.

Stunning-Narwhal1884

Big day for NTLA

No_Acanthaceae_2198

Thanks! I've been trading on NTLA for months. I know this one better than most stocks.

cyclingmania

Why did NTLA tank on positive news whyyy?

Status-Net2947

NTLA mtherfker lol

BaxBaxPop

NTLA Gene editing biotech is about to see some approvals. Things gonna blow up.

Danakil

NTLA will announce they have the HAE cure and the first in-vivo treatment which is actually commercially viable unlike the CRSP ex-vivo cure. If data is good, they will go from market cap of 1.6B back to 10B in the next year since the HAE market is substantial.

Danakil

NTLA is going to blow up with a huge short squeeze when they announce they are the first to have an in-vivo cure at 8am tomorrow.

Upset-Motor-2602

NTLA$13.63 ▲ +2.4% reg / +19.3% AH

Professional_Help_85

Anyone follow the CRISPR space? what do you think happens tomorrow after NTLA top line data?

ooh4uups

The $160 peak was fundamentally driven by excitement around NTLA-2001 (ATTR) and NTLA-2002 (HAE), representing the potential of CRISPR to deliver curative therapies. However, dilution from significant capital raises, inherent clinical/execution risks, market volatility, and a reassessment of valuation expectations have prevented the stock from sustaining that level. Future gains depend on successful clinical milestones, regulatory approvals, and commercial execution, but the path back to $160 is steep due to the factors above.

Professional_Help_85

Anyone saw that CRSP NTLA shake out? What do you make of it

No_Acanthaceae_2198

I wonder if anyone got in NTLA (not a penny) after I posted. If so, congrats. Jumped $2 on news.

No_Acanthaceae_2198

Not a penny, but shorts are hitting NTLA hard right now. Already a heavily shorted stock.

Snoo23417

Why the hell is NTLA down 10%?

No_Acanthaceae_2198

I'm holding nothing but my NTLA shares (one of my most consistent day trades but dipped under my buy-in so I'll wait it out). I trust very little in this market, with this war, with these politics.

Bubbly-Treacle-4334

NTLA has had an 11% drop in short interest in the last week and is STILL one of the most shorted biotechs. Remainers have about 7 days to exit and this stock is looking very positioned for a run up over the next 2 months. Massive positive sentiment and still a possible short sweez scenario

Bubbly-Treacle-4334

NTLA: $13.55 Crispr Bio 90% Institutional ownership 40% short interest FDA Holds removed March 2nd 8 Buy ratings since ranging from $18 to $100 with the average around $25 2 anticipated catalysts with research reports coming in the Summer and Fall Run up is coming with potential short squeez and even without the squeeze this is a solid hold

Bubbly-Treacle-4334

been trying to tell yall about NTLA

Bubbly-Treacle-4334

Why are we not jumping in NTLA for a short squeeze deez nutz? Like, light retail attention could blow that shit up

Bubbly-Treacle-4334

Look up NTLA's recent ratings and price prediction and then look how many shorts are stuck in positions they built before the FDA lifted a hold on their research. The most interesting stock I've come across in a while. Risky but looking pretty fucking good for a long play

Bubbly-Treacle-4334

What yall thinking about NTLA? Big short interest based on an FDA hold that was lifted on March 2nd but shorts still haven't covered.

Snoo23417

She's a major NTLA investor now. Unfortunately so am I.

cerebrump1

I admit that NTLA is not pennystock, thank you for stating your interpretation.

Polishzebracamel

NTLA is not a penny stock. But good for you for findings it. This is the April play. Phase 3 data is released in April. The call to put ratio is crazy bullish. Look at the April $20/25$ calls. Intellia is hiring like crazy for commercialization. Currently #2 most shorted stock. It either means the shorts know and have know since the beginning of phase 3 ,after seeing 97% success rate for HALEO that it's going to fail OR they piled in after the patient died in magnitude. Now all the issues have resolved, except the guy is still dead. Phase 3 data is coming out next month, check any AI model, it's an 85% success rate, because I don't know anything about science I trust AI. Either you lose half in April on bad phase 3 data( 20% chance I would say) or %100 gain MINIMUM because of the shorts. Some analysts say it's a $100 stock, it's been there before. I think it's going to 34$ on good news by end of May. Good find. I've tried to post this on wsb but don't have enough karma or whatever

shaqballs

Ah yes NTLA my favorite “penny stock”

acceinvestments

Good that you're starting, seriously most people just don't. Honest feedback though, you've got 15 positions across $900. That's a lot of complexity for not much capital yet. Each position is basically a rounding error and the transaction costs plus mental overhead of tracking all this isn't really worth it at this stage. The speculative stuff specifically (JOBY, ACHR, NTLA, EDIT) these are genuine moonshots. Not saying they can't work but at $12-25 each they're not moving your portfolio if they 10x, and they can go to zero. EDIT is already down massively from its highs and the gene editing space has been brutal for smaller players. Three gene editing stocks (CRISPR, NTLA, EDIT) is also a lot of overlap in a sector that's still years from widespread clinical revenue. What I'd actually do in your position: simplify hard. VOO as the core, maybe one or two high conviction individual names you genuinely understand and believe in, and just keep adding the $400/month consistently. At this portfolio size compounding on VOO alone will outperform the complexity of managing 15 positions. The instincts are there, semiconductors, defense, biotech are real themes. But the execution is spread too thin to matter yet. What's the thesis on JOBY and ACHR specifically? Genuine question, just curious what drew you to both.

Valkyrie_Skuld

NTLA did an ATM offering I think it basically caps their price at ~15

Western_Knee674

Day 2 of the world missing the short squeeze set up perfectly for NTLA….

Western_Knee674

NTLA, was at 28 and got hammered because of death in clinical trial and fda pause. Death was unrelated to drug and fda resumed trial with minimal changes yesterday. 40% short interest with great data so far in their multiple phase 3 trials

Western_Knee674

Does nobody care about NTLA? Just got off fda hold, 40% short interest, this used to be the whole point of posting here

redego66

Participating in Shorts slaughter on $NTLA around market open

RetireinGrenada

40% short and FDA hold is going to get lifted. NTLA Set those sell orders HIGH

dvdmovie1

I like investing in biotech, have never invested in EDIT (or CRSP, NTLA are other ARKG-ish names that have often come up.) "biotech winter" There's a lot of things that have done well. XBI actually had a good year last year. " if literally anything goes right (data, partnership, asset sale, etc) the stock could reprice hard." True, but at $2, you have to take into account that a lot EDIT-specific has not gone right, it isn't just the sector. This isn't down 97% since late 2021 because of factors beyond the company.

No_Acanthaceae_2198

I like picking up the pieces on oversold biopharma (as long as it has a pretty solid chance and continuing). I made good money on NTLA doing that. In with 9k shares.

Mayhem370z

NTLA keeps creeping higher and higher then cools off. It used to be at $27 and due to a botched trial, caused it to go down to $9. The botched trial if I remember right wasn't related to what they were trailing but the patient did die so the correlation scared holders.The hault just got lifted. So I'm definitely gonna buy all these pull backs.

No_Acanthaceae_2198

Not a penny stock but practically was this fall, I'm so stoked the hold has been lifted on NTLA. I loaded that fall dip and have been holding for a while.

BleuBrink

Man I bought NTLA years years ago, while they were in lawsuit with another company over the tech. I sold 20% down and shortly after they won the suit. Man I didn't learn back then how to hold stocks yet.

Cl0wnbby

CRSP and NTLA are have the biggest potential in gene editing.

BaxBaxPop

NTLA. I keep saying it every day.

BaxBaxPop

NTLA!

BaxBaxPop

Anyone taking about NTLA here? Great WSB play. Trading at $26 in fall based on expectations of approval of HAE gene therapy treatment, had a patient die in phase 3 and an FDA hold. Stock dropped to $8. Turns out patient died of unrelated surgical complications. Stock now surging based on expectations of lifting FDA hold. Back up to $13.50 now and very likely headed back to $20s. Also, with the death, there's a 35-40% short float getting...dare I say it...squeezed!

jusjones314

Whelp Cathie is loading up on NTLA... might as well burn my lil calls 😢😢😢

jusjones314

APLD and NTLA for next week... Get some lottos, they're cheap and you don't need the money anyway 🤷🏾‍♂️

Keizman55

The tracker doesn't show what happened after assignment. I saw that FIG, PRME got assigned away for more premium, but your tracked doesn't show the profit on the shares. I see that you also ran CCs on ACHR, NTLA, but no assignement yet, so still holding them? Are you still holding RCAT? FLY? DNA? Looks like they all may have recovered since assignment, although not sure what price you were assigned at and on what date. Is there away to add columns in the tracker to show the full chain of events after assignment?

No_Acanthaceae_2198

Add to that NTLA. One of these days they'll get the pass to keep going. It was one patient out of hundreds who already had significant morbidities being overweight and elderly who caused the trial pause. The stock is so crazily shorted right now. One of these days in the next couple of months it's going to explode.

haze_from_deadlock

This is how I feel with NTLA

Professional_Help_85

Surprised no one mentioned CRISPR stocks like CRSP NTLA CRBU

haze_from_deadlock

The only reason to care about spot price over market cap is if you are buying a contract that specifies a minimum of 100 units or something (like a call option). Do you have $1000 to invest and want to buy a call? I think NTLA could definitely rebound to the $15-20 price point if its clinical trial that was halted resumes.

BaxBaxPop

TSLA: FSD solved + Cybercab = Big Growth RKLB: Neutron = Big Growth NTLA: Gene editing treatments almost ready for primetime. NTLA got excessively beaten up for one Phase 3 death and a FDA pause. Should bounce back fully in 2026. Possible 2021 highs if data looks really good.

WhiteLotus_777

this aged well lol went from 100% to 0% profit on NTLA !

MoistAbuelita

Thoughts on NTLA boys? Easy 2x?

haze_from_deadlock

muh NTLA

Potential-Reporter66

Along with CRBU, have you looked at EDIT and NTLA? One person that ties these all together is Jennifer Doudna. Looking into her was how I found out about CRBU years ago. I agree with their financial responsibility, and they've maintained it over the years. I think this with the relationship to Doudna are important as the companies are serious and aren't at risk of "being stupid" (e.g. out of nowhere turning into a crypto treasury company like Leap Therapeutics). If you are able to share those RE tickers, I would like to know or at least know a good source for them to save me a search. Would appreciate it greatly.

Prestigious_Age5422

Have to say, I recently lost a ton of money in NTLA. Hoping this one is a grower and I can sell in the green 😅

Orange_Codex

Not a penny but Intellia Therapeutics (NTLA) is a bargain right now. Stock plunged because a patient with pre-existing conditions died during a Phase 3 trial, pausing it, but there's little to indicate the treatment itself (nex-z) was responsible.

Competitive-Ad4708

Um... i just loaded up on a bunch of NTLA. Anyone else want to get rich with me?

Envirocare1

Cathie Wood also bought NTLA

pbj37

No it’s not entirely new I agree. What’s new is it working for multiple cancers and the potential for multiple chemo options with the enhancer molecule added in combination which is protected by patent for this specific combination and has protection for other combinations. It’s a platform not just a single drug they are making. I didn’t say it’s the number one reason they don’t work. I said it’s a big reason. Take a look at NTLA and their phase 3 that’s on pause right now because of one patient’s DILI. Phase three has more patients so yes what was true of safety and efficacy in small cohorts in phases 1 and 2 may be invalidated. Probably the number one reason is efficacy doesn’t pan out in 3 as compared to 2 like you said though. Their dilution was at a much better valuation than their last dilution. I’m excited for the phase 2 triple negative breast cancer results. Cheers

jameskwonlee

Picking up some NTLA calls for earnings. I might be wrong, but looks like the shorts covered on bad news @ around 10 bucks pre-market, and the thing has quieted, i.e. calls are cheap. I'm not a degen gambler though, so do your own research.

YardElectronic5722

Bottom is in on NTLA. I capitulated.

No_Acanthaceae_2198

Watch NTLA. It'll rebound. It's expected to bottom out soon with a much higher price target in the next three months.

krazay88

Holy shit i just noticed how NTLA got absolutely crushed the other day! Absolutely insane dump, I’ve learned my lesson already with bio stocks, but wow thank god I didn’t get greedy and buy into it after I had successfully rode the CRSP pump.

Illustrious95

That NTLA v just bought me a new lambo

rafpe

Sounds like NTLA

Fleetfox17

NTLA isn't just a regular biotech stock. They're at the forefront of a revolutionary technology that will change the world the same way the computer did.

haze_from_deadlock

After yesterday's NTLA meltdown, doesn't that have more upside from a rebound?

Illustrious95

NTLA made me more than Nvda in the today lmao

WuTangNameGenerat0r

I thought NTLA was short for nutella and now I’m broke

CapnMack

Yeah that was a great lesson for me. I bought at $1.12, and saw that 7x and thought it would keep going. Then I held when it dipped, and went back to $4. And I should have sold then, but thought it would go up so I waited. Then I saw $3.50 and thought I’d wait for it to go back to $4. Then it went to 2.90 and I thought I’d wait until it went to $3. And then I finally sold at $2.76. Still made a couple grand, but not what I could have! First time trading, this taught me a lot 😆. Taking emotion and hope out and approaching things moving forward with more calculation and having firm entry and exit positions. Bought ASST this morning at $1.47 and when it stayed at $1.50 for a couple hours I just sold and looked at NTLA’s dip and bought in there at $13.70. That’s back up to $14.70, I’m going to get out of there soon too.

TestingLifeThrow1z

Y'all having a great day while I sit on NTLA.

mmoney20

I'm looking at $NTLA as well. One thing I don't like is that stock recovery isn't 100% post-event. I might trade sideways for a bit before moving back up. Examples below didn't really recover and still well below pre-event. Some concerns chatGPT shared with me: Here are a few recent situations that closely map to the scenario you’re dealing with (lead asset, trial pause, safety event) — with how they played out. • Rocket Pharmaceuticals (RCKT) – gene therapy for Danon disease A patient in their Phase 2 pivotal trial (RP-A501) died following a capillary-leak syndrome and acute systemic infection. → The trial was voluntarily paused and the FDA placed a hold. → Stock plunged \~60% intraday. → Later resumed with lower dose; stock recovered \~20% but stayed below prior levels. Takeaway: Safety event ⇒ big drop; resumption ⇒ partial rebound. • Sarepta Therapeutics (SRPT) – gene therapy for Duchenne muscular dystrophy (DMD) Two patient deaths from acute liver failure triggered a pause in shipments and trials. → Stock dropped >40% on the news. Takeaway: Even approved products face serious valuation risk after safety events. • Novavax (NVAX) – vaccine candidate trial hold A motor-neuropathy case in a Phase 2 trial led to an FDA clinical hold. → Stock dropped \~19%. Takeaway: Safety issue in even lower-risk areas causes sharp market reactions. • Intellia Therapeutics (NTLA) One patient developed Grade 4 liver enzyme elevation → company paused dosing in Phase 3 MAGNITUDE trial of nex-z. → Shares fell \~45% pre-market. Important nuance: single patient (\~450+ dosed), appears reversible but still triggered protocol pause. Watch: causality, regulator feedback, protocol changes, resumption timeline.

Professional_Help_85

Ouch NTLA baggies made today

idk-rogue

Thoughts on NTLA?

Xzlk

How is NTLA not at $5 right now? Expected value is 0. Another Cathie masterclass.

ALittleWorseEveryday

Wow NTLA down almost 50% did they find something bad in the Nutella or something

FoxCoding

Maybe don't panic sell NTLA. I saw another post where the OP says there are health concerns in their trials, but it only happened to one very old dude who is doing fine now. If that is true, this sounds like market overreaction and it will go back up. I don't know if it is, I'm at work and I can't do my own research, but it does sound like it. If that is actually an overreaction, selling now is unwise. It's important to note that I have no skin in the game, so it's easy for me to say what I am saying. I wish I could actually research this, as, if the previous post is accurate, this seems like a good chance to get some quick returns from the overreaction.